United Therapeutics Corporation annual free cash flow for fiscal 2025 was $1.0 billion, a decrease of 4.2% from $1.1 billion in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $1.0B | $1.1B | $748M | $664M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Free Cash Flow | $362M | $173M | $346M | $130M | $386M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More UTHR metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS
All UTHR financial statements → Interactive UTHR charts →
About TickerBase · Data methodology & sources